Crispr Library Screening: Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma (Adv. Sci. 17/2019)

In article number 1900782, Xudong Wu, Tao Jiang, and Chunsheng Kang, and co‐workers present a genome‐wide screening under a clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 library. Notably, E2F6 was proven to drive the temozolomide (TMZ) resistance of 191 glioblastoma‐related...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kai, Liu, Xing, Li, Yansheng, Wang, Qixue, Zhou, Junhu, Wang, Yunfei, Dong, Feng, Yang, Chao, Sun, Zhiyan, Fang, Chuan, Liu, Chaoyong, Tan, Yanli, Wu, Xudong, Jiang, Tao, Kang, Chunsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Frontispiece
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724468/
http://dx.doi.org/10.1002/advs.201970103
Descripción
Sumario:In article number 1900782, Xudong Wu, Tao Jiang, and Chunsheng Kang, and co‐workers present a genome‐wide screening under a clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 library. Notably, E2F6 was proven to drive the temozolomide (TMZ) resistance of 191 glioblastoma‐related candidate genes. To silence the expression of E2F6 is a promising strategy to conquer TMZ resistance in glioblastoma. [Image: see text]

Ejemplares similares